Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(33.3%)
N/A
1(33.3%)
Phase 1
1(33.3%)
3Total
Phase 2(1)
N/A(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07464028Phase 2Not Yet Recruiting

Terazosin And Metabolic Energetics in Parkinson's Disease

Role: lead

NCT07288450Phase 1Not Yet Recruiting

Terazosin And Metabolic Engagement in Parkinson's Disease

Role: lead

NCT06984757Not ApplicableEnrolling By Invitation

Mid-frontal Delta/Theta and Cognitive Control

Role: lead

All 3 trials loaded